Why the study?
Does endothelin-1 infusion alter systemic and renal hemodynamics compared to endothelin-3 in healthy volunteers?
Does endothelin-1 infusion alter systemic and renal hemodynamics compared to endothelin-3 in healthy volunteers?
The systemic and renal vasoconstrictor effects of endothelin-1 in humans are predominantly mediated by ETA receptors, as ETB-selective stimulation with endothelin-3 produced no hemodynamic or renal effects.
Answers are grounded in this paper and cite their sources.
ETA selectivity likely mediates ET-1 renal effects in humans; leaves open therapeutic translation to disease states.
The authors recently reported that infusion of endothelin-1 in humans to obtain pathophysiological plasma levels causes profound renal vasoconstriction and sodium retention. The relative roles of the ETA- and ETB-receptor subtypes in these effects in humans is unknown. Such information is essential in view of the recent introduction of endothelin-receptor blockers in clinical medicine. The study presented here was designed to define the role of the ETA- and ETB-receptor subtypes in the renal actions of endothelin-1 in humans. Systemic infusion of endothelin-1, a nonselective receptor agonist, was compared with infusion of equimolar dosages of the ETB-selective agonist endothelin-3 in healthy volunteers. Endothelin-1 infusion was associated with an approximate 2.5-fold increase in plasma levels of endothelin-1. This was accompanied by an increase in blood pressure by approximately 6 mm Hg (P < 0.05). During endothelin-1 infusion, RPF decreased from 642 +/- 42 to 480 +/- 36 mL/min (P < 0.05) and GFR from 121 +/- 4 to 109 +/- 7 mL/min (P < 0.05). Sodium excretion rate decreased during endothelin-1 infusion, from a baseline value of 182 +/- 33 to 84 +/- 28 mumol/min at the end of the endothelin-1 infusion. Endothelin-3 infusion also resulted in a approximate 2.5-fold increase of plasma levels of endothelin-3. However, in contrast to the endothelin-1 infusion, endothelin-3 had no effect on blood pressure, renal hemodynamics, and electrolyte excretion. These results suggest that the systemic and renal vasoconstrictor effects of endothelin-1 in humans are predominantly mediated by the ETA receptors.
No takes yet. Share an insight, caveat, or question.
Kaasjager et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: